American biotechnology company Moderna said on Tuesday that its Covid-19 vaccine showed promise in a lab setting against coronavirus variants, including the highly contagious Delta variant first identified in India. The results came from vitro neutralisation studies of sera from eight participants one week after they received the second dose of the Moderna Covid-19 vaccine, according to reports.
The vaccine produced neutralising titers against all variants tested, including additional versions of the Beta variant, scientifically named B.1.351 which was first identified in South Africa; three lineage variants of B.1.617 which was first identified in India, including the Kappa (B.1.617.1) and the Delta variant (B.1.617.2); the Eta variant (B.1.525) which was first identified in Nigeria; and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola, respectively, according to Moderna.
"These new data are encouraging and reinforce our belief that the Moderna Covid-19 vaccine should remain protective against newly detected variants," said Chief Executive Officer of Moderna Stephane Bancel.
Cipla seeks consent from DCGI to import Moderna COVID-19 vaccine
Study Reveals: Pfizer, Moderna Vaccines Likely Induce 'Persistent’ Immunity to COVID
Poland Health Ministry Report: No Covid deaths in Poland after 15 months